Fundamental and clinical studies of biomarkers have established the contribution of inflammation to the development of atherosclerosis [6] and that anti-inflammatory drugs (including GLP-1 receptor agonists) can improve cardiovascular outcomes [21]. Here, GLP1R is linked to atherosclerosis.